Monopar Therapeutics Inc.

What they do

Monopar develops treatments for unmet medical needs, centered on ALXN1840 (tiomolibdate choline), a copper-chelating therapy for Wilson disease, and the MNPR-101 radiopharmaceutical programs. The company has reported no revenue in any period and funds operations through equity financings. It is preparing commercial infrastructure for a potential ALXN1840 launch while continuing clinical development of its radiopharmaceutical candidates.

Revenue drivers

• ALXN1840 (tiomolibdate choline) for Wilson disease — Lead program and only near-term revenue candidate; a rolling NDA submission was initiated July 22, 2026, with the company anticipating completion within the next few months. No revenue has been recognized to date.
• MNPR-101 radiopharmaceutical programs — Earlier-stage radiopharmaceutical therapeutic and imaging candidates. Company statements describe continued development of MNPR-101 programs, but no revenue or approval exists.
• Pediatric Priority Review Voucher (potential) — FDA granted Rare Pediatric Disease designation to ALXN1840 on June 30, 2026; at NDA approval the company could receive a PRV that it may use, sell, or transfer. Contingent and non-recurring.

Recent performance

Second quarter 2026 net loss was $5.3 million, or $0.62 per share, versus a $2.5 million loss, or $0.35 per share, in the second quarter of 2025. R&D expense rose to $4,766,832 from $1,730,000, an increase of $3,036,831, primarily attributed to a $2,026,851 item and other program costs. Cash, cash equivalents and investments were $134.3 million as of June 30, 2026. Full-year 2025 net loss was $13.7 million, with operating cash flow of negative $12.2 million. Revenue has remained $0.00 in every reported period.

Strategy

The stated priority is the rolling NDA submission for ALXN1840 and potential commercial launch, supported by new commercial hires and board additions. The company is building commercial readiness with Susan Rodriguez as Chief Commercial and Strategy Officer, Nicole Sweeny on the board, and Sharon Funk and Daniel Olmstead in sales, marketing and market access roles. It also plans continued development of MNPR-101 programs and internal research and development. Management states current funds support operations through at least December 31, 2027.

Risks

• No product revenue — Monopar has reported $0.00 revenue in every period shown and depends on financing, with an accumulated deficit funded by equity raises.
• Regulatory and NDA timing risk — Completion of the ALXN1840 rolling NDA and FDA review are uncertain, and the company cites potential delays, additional expenses and U.S. government shutdown impacts on regulatory timelines.
• Funding and milestone obligations — The company cites the need to raise sufficient funds for development, potential commercialization and contractual future milestone payments, including under license and purchase agreements such as those with Alexion, XOMA and Tactic Pharma.
• Radiopharmaceutical supply and shelf-life — Monopar cites risks in obtaining adequate radioisotope supply at reasonable cost and fulfillment challenges from the time-limited shelf-life of its radiopharmaceutical programs.

Outlook

Management anticipates completing the ALXN1840 NDA submission within the next few months and says current funds support operations through at least December 31, 2027, including regulatory and potential commercial activities for ALXN1840, continued MNPR-101 development, and internal R&D. The company is staffing commercial functions ahead of a possible launch, contingent on approval. No revenue guidance is provided.